Flupenthixol PCD Pharma Franchise Company
Cafoli Lifecare offers a Flupenthixol PCD pharma franchise built on 2 formulations spanning oral tablets and depot injection, manufactured at WHO-GMP certified facilities. This gives franchise partners a specialised psychiatry and CNS line for psychiatrists and physicians.
What is Flupenthixol?
Flupenthixol is a thioxanthene antipsychotic that acts mainly by blocking dopamine D1 and D2 receptors. At low doses it has mood-elevating, anxiolytic and antidepressant properties (often combined with melitracen), while at higher doses and as a long-acting depot it is used to manage psychosis. Read its profile on PubChem.
Therapeutic Applications
Flupenthixol is used, in low-dose combination with melitracen, for anxiety and depression with somatic symptoms, and as a higher-dose oral or long-acting depot injection for the maintenance treatment of schizophrenia and other chronic psychoses. Prescriptions come mainly from psychiatrists, neuropsychiatrists and consultant physicians.
Why Flupenthixol is a High-Potential Molecule for Distributors
The low-dose flupenthixol-melitracen combination is very widely prescribed in Indian general and psychiatric practice for mixed anxiety-depression with physical symptoms, giving strong outpatient volume, while the depot injection secures a maintenance niche for chronic psychosis with guaranteed periodic reuse. As mental-health awareness grows and treatment gaps close, both channels are expanding — a durable, dual-format molecule for distributors.
Why Choose Cafoli Lifecare
Cafoli Lifecare provides territory-wise monopoly rights, WHO-GMP certified manufacturing, DCGI-approved formulations, complete promotional inputs and the backing of 1000+ franchise partners across India.
References
- PubChem: Flupenthixol
- PubMed: Flupenthixol literature
Our formulations of Flupenthixol find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: